Department of Neurology

AGENCY

TITLE

PERIOD OF SUPPORT

 Epilepsy:

Eisai Medical Research Inc.

A Double-blind, Placebo-controlled, Parallel-group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures

09/07/06-09/06/09

GlaxoSmithKline

Randomized double blind placebo controlled parallel group study to assess the effects of Lamotrigine extended-release tablets on comorbid depressive symptoms in subjects with epilepsy

07/01/07-06/30/08

GlaxoSmith Kline

Lamotrigine extended release in elderly patients with epilepsy

7/11/07-7/10/08

GlaxoSmith Kline

Multicenter double blind randomized conversion to monotherapy comparison of two doses of Lamotrigine for the treatment of partial seizures LAM30055

6/28/07-6/27/08

INC Research Inc

Double blind placebo controlled dose esculation parallel group study of E2007 given as adjunctive therapy in patients with refractory partial seizures

6/22/05-4/30/07

Pfizer

Randomized double blind placebo controlled parallel group multi-center trial of Pregabalin versus placebo in the treatment of neuropathic pain associated with HIV neuropathy

05/04/10-05/31/11

PPD Development, LLC

A Double-blind, Placebo-controlled, Dose Escalation, Parallel-group Study to Evaluate the Efficacy and Safety of E2007 (Preampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures

12/05/08-12/04/10

PPD Development, LLC

14 month open label extension phase of the double blind placebo controlled dose escalation parallel group studies to evaluate the efficacy and safety of E2007 (perampanel) given as adjunctive therapy in subjects with refractory partial seizures

12/05/08-12/4/10

PRA International

Multicenter double blind historical control randomized conversion to monotherapy with Keppra XR for treatment of partial onset seizures study AND an open label long term follow up study with Keppra XR for treatment of partial onset seizures

07/24/07-07/23/10

PRA International

Open label extension study of Rufinamide given as adjunctive therapy in patients with refractory partial onset seizures

5/14/07-5/13/09

Quintiles

Randomized double blind parallel group multicenter study to evaluate the retention rate, efficacy, safety and tolerability of Carisbamate, Topiramate and Levetiracetam as adjunctive therapy in subjects with partial onset seizures

05/21/08-12/31/09

Quintiles, Inc.

A Multi-center, Open-label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients with Partial-onset Seizures (Extension of Study VRX-RET-E22-301)

4/11/06-4/10/11

Quintiles, Inc.

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Phase 3 Study to Determine the Efficacy and Safety of Retigabine used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-onset Seizures

12/6/06-12/5/09

Schwarz Biosciences

Historical controlled multicenter double blind randomized trial to assess the efficacy and safety of conversion to Lacosamide 400 mg/day monotherapy in subjects with partial onset seizures 

07/18/07-07/17/10

Schwarz Biosciences

Multicenter open label extension trial to assess the long term use of Lacosamide monotherapy and safety of Lacosamide monotherapy and adjunctive therapy in subjects with partial onset seizures

07/18/07-07/17/10

Schwarz Biosciences, Inc.

Open label extension trial to determine safety and efficacy of long term oral SPM927 in patients with partial seizures

10/25/05-10/24/10

Sepracor

Efficacy and safety of Eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures

03/10/10-03/09/11

 UCB Pharma

Bone health in patients with epilepsy treated with Levetirecetam

 5/18/04-1/14/08

Headache: 

Drexel University

Interictal, Ictal and Post-Treatment Adipocytokine Levels in Migraine

11/19/08-11/18/10

GlaxoSmith Kline

vWF as a Marker for Endothelial Dysfunction in Female Migraineurs

11/1/05-10/31/09

GlaxoSmith Kline

Evaluation of Laboratory Samples from Study Entitled:  Brain Lesions in Migraine:  The Relationship to Endothelial Dysfunction"

11/7/08-4/1/10

GlaxoSmith Kline

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of TREXIMA

10/9/07-10/8/09

MAP Pharmaceuticals Inc

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of MAP0004 in Adult Migraineurs for a Single Migraine episode

1/1/10-12/31/10

GlaxoSmithKline

Double blind, single migraine attack, placebo controlled, parallel group multi-center study to evaluate the efficacy and tolerability of Trexima TM (Sumatriptan Succinate/naproxen Sodium) tablets vs placebo when administered during mild pain phase of menst

3/24/06-3/23/07

GlaxoSmithKline

A study of combination product (sumatriptan succinate and naproxen sodium) in migraine subjects who report poor response or intolerance to Eletriptan (study 2 of 2) TRX106573

11/13/06-9/12/08

Multiple Sclerosis: 

Genzyme Corporation

Phase 3 randomized rater and dose blinded study comparing two annual cycles of intravenous low and high dose Alemtuzumab to three times weekly subcutaneous Interferon Beta-1a (Rebif) in patients with relapsing remitting Multiple Sclerosis

07/28/08-07/27/09

Mount Sinai NY

Multi-Center double blind randomized study comparing the combined use of Interferon Beta-1a and Glatiramer Acetate to either agent alone in patients with relapsing remitting multiple sclerosis (CombiRx-Phase III)

08/01/04-11/30/10

NINDS

Biomarker in MS – A sub-study of Combi-Rx

06/01/05-05/31/10

Novartis

Protocol No. CFTY720D2309

02/26/07-03/08/11

Parkinson's Disease: 

Acadia Pharma-ceuticals, Inc.

A Multi-center, Placebo-controlled, Double-blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

7/22/08-7/21/09

Acadia Pharma-ceuticals, Inc.

A Multi-center, Open-label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

10/1/08-9/30/09

Cornell University

Effects of Coenzyme Q10 in Early Parkinson's Disease - Phase III QE3 Study

12/1/07-11/30/10

CroMedica Inc.

Multi-center, Multi-national, Phase III, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial of the Efficacy and Safety of Rotigotine CDS Patch in Subjects with Advanced Stage, Idiopathic Parkinson's Who are not Controlled on Levodopa

1/23/02-12/17/09

Eisai Medical Research Inc

A Multi Center Open Label Extension Study to evaluate the long term safety, tolerability and efficacy of E2007 as an adjunctive therapy in Levodopa treated Parkinson’s Disease patients with motor fluctuations

3/28/07-9/30/09

Impax Laboratories

A study to evaluate the safety and efficacy of IPX066 in Advanced Parkinson’s Disease, Protocol no. IPX066-B09-OS (the “Protocol”)

11/9/09-11/8/10

GlaxoSmith Kline

The Impact of Switching to Continuous Release Dopamine Agonists on Non-motor Side Effects

10/24/05-10/23/09

Neurogen Corporation

A randomized double blind placebo controlled study to assess the efficacy and safety of three doses of aplindore MR (1,3, and 6 mg twice daily) in patients with early Parkinson’s Disease

10/1/08-10/31/09

PPD, Inc.

An Open Label SLV308 Extension to Study S308.3.002 in Patients with Parkinson's Disease Experiencing Motor Fluctuations

6/18/07-6/17/10

Quintiles, Inc.

An Open-label Extension Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169

4/14/04-4/13/10

Schering Plough Corporation

A Phase 2, 36-week, Open-label, Uncontrolled Safety Followup Study Assessing SCH 420814 5 mg BID

9/10/08-9/9/09

Schwarz Biosciences, Inc.

A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects with Advanced-stage Parkinson's Disease

7/24/07-7/23/09

TEVA Neuroscience

An open label multi center follow up study designed to evaluate the long term effects of Rasagiline in Parkinson’s Disease subjects who participated in the ADAGIO study

7/20/09-7/19/10

TEVA Neuroscience

Investigation of the occurrence of Serotonin Toxicity in Parkinson’s Disease patients treated concomitantly with Rasagiline and antidepressants using retrospective chart review

9/28/09-9/27/10

University of Rochester

Parkinson's Disease Collaborative Study of Genetic Linkage, 'PROGENI'

2/1/06-1/31/10

University of Rochester

A Longitudinal Observational Follow-up of the PRECEPT Study Cohort (PostCEPT)

1/1/07-12/31/10

University of Rochester

Evaluation of blood biospectroscopy as a novel diagnostic test for idiopathic Parkinson Disease (PD Biospec) – SPIN-PD

8/4/09-3/31/13

Stroke:

Boehringer Ingelheim

PRoFESS – Prevention Regimen for effectively avoiding second strokes: a double blind, active and placebo controlled study of Aggrenox vs. Clopidogrel + Aspirin with and without Micardis

3/26/04-12/17/08

Boston Scientific Corp

Boston Scientific EPI: A Carotid Stenting Trial for high risk surgical patients

8/19/02-8/18/08

Duke University

Adherence Evaluation After Ischemic Stroke Longitudinal Registry (AVAIL)

7/19/06-7/18/10

Guidant Corp

Carotid RX Acculink/Accunet Post-Approval trial to uncover unanticipated and rare events (CAPTURE 2)

7/7/06-7/6/10

Merck

Protocol No. 034 (Stroke)

5/20/08-5/19/10

Mitsubishi Tanabe Pharma Corporation

A Phase I, Double Blind, Placebo Controlled, Ascending-Dose, Clinical Study investigating the safety, tolerability and pharmacokinetics of MP-124 in acute, ischemic stroke patients

1/28/10-1/27/10

Mount Sinai

Future Revasularization Evaluation in patients with diabetes mellitus: optimal management of multivessel disease (FREEDOM)

8/16/06-12/31/09

NMT Medical

Safety and Efficacy of the STARFlex Septal Closure System vs Best Medical Therapy in Patients with a Stroke and/or Transient Ischemic Attack Due to a Presumed Paradoxical Embolism through a Patient Foramen Ovale  (CLOSURE 1)

7/18/03-5/19/10

Schering Plough Research Institute

Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients with Atherosclerosis (Study P04737)

2/27/08-2/26/11